HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.
An expert company called HC Wainwright still thinks Immunic is a good stock to watch and believes it could be worth $22 per share. When experts keep their positive outlook, it means they still see reasons to believe in the company's future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.